Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance
Reference number: TA322
Published: 24 September 2014
Last updated: 26 June 2019

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination document

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination document

Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination document
20 August 2014
(445.75 Kb 9 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 19 August 2014